1
|
Zhang M, Adeniran AJ, Vikram R, Tamboli P, Pettaway C, Bondaruk J, Liu J, Baggerly K, Czerniak B. Carcinoma of the urethra. Hum Pathol 2017; 72:35-44. [PMID: 28827100 DOI: 10.1016/j.humpath.2017.08.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2017] [Revised: 07/26/2017] [Accepted: 08/10/2017] [Indexed: 01/05/2023]
Abstract
Primary carcinomas of the urethra are rare and poorly understood lesions; hence, their clinical and pathologic spectrum is not completely defined. We analyzed a series of 130 primary urethral tumors and classified 106 of them as primary urethral carcinomas. The age at diagnosis of patients with primary urethral carcinomas ranged from 42 to 97 years (mean, 69.4 years; median, 70 years). There were 73 male and 33 female patients with a ratio of 2.2:1. In male patients, the tumors most frequently developed in the bulbous-membranous segment of the urethra. In female patients, the entire length of the urethra was typically involved. Microscopically, they were poorly differentiated carcinomas with hybrid squamous and urothelial features and developed from precursor intraepithelial conditions such as dysplasia and carcinoma in situ, which were frequently present in the adjacent urethral mucosa. High-risk human papilloma virus infection could be documented in 31.6% of these tumors. Follow-up information was available for 95 patients. Twenty-three patients died of the disease with a mean and median survival of 39 and 21 months, respectively. Urethral carcinomas are aggressive tumors with a high propensity for regional and distant metastases with mean and median survival of 39 and 21 months, respectively. Our observations have important implications for the management of patients with primary carcinoma of the urethra by defining them as a unique entity linked to human papilloma virus infection.
Collapse
Affiliation(s)
- Miao Zhang
- Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
| | | | - Raghunandan Vikram
- Department of Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
| | - Pheroze Tamboli
- Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
| | - Curtis Pettaway
- Department of Urology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
| | - Jolanta Bondaruk
- Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
| | - Jinsong Liu
- Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
| | - Keith Baggerly
- Department of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States
| | - Bogdan Czerniak
- Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States.
| |
Collapse
|
2
|
Bryce AH, Borad MJ, Egan JB, Condjella RM, Liang WS, Fonseca R, McCullough AE, Hunt KS, Ritacca NR, Barrett MT, Patel MD, Young SW, Silva AC, Ho TH, Halfdanarson TR, Stanton ML, Cheville J, Swanson S, Schneider DE, McWilliams RR, Baker A, Aldrich J, Kurdoglu A, Izatt T, Christoforides A, Cherni I, Nasser S, Reiman R, Cuyugan L, McDonald J, Adkins J, Mastrian SD, Von Hoff DD, Craig DW, Stewart AK, Carpten JD. Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. Clin Genitourin Cancer 2016; 15:e727-e734. [PMID: 28057415 PMCID: PMC7513310 DOI: 10.1016/j.clgc.2016.11.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Accepted: 11/20/2016] [Indexed: 11/29/2022]
Affiliation(s)
- Alan H Bryce
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN.
| | - Mitesh J Borad
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN
| | - Jan B Egan
- Center for Individualized Medicine, Mayo Clinic, Rochester, MN
| | | | | | - Rafael Fonseca
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN
| | - Ann E McCullough
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ
| | | | | | - Michael T Barrett
- Mayo Clinic Cancer Center, Phoenix, AZ; Translational Genomics Research Institute, Phoenix, AZ
| | | | - Scott W Young
- Department of Radiology, Mayo Clinic, Scottsdale, AZ
| | - Alvin C Silva
- Department of Radiology, Mayo Clinic, Scottsdale, AZ
| | - Thai H Ho
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN
| | - Thorvardur R Halfdanarson
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN
| | - Melissa L Stanton
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ
| | - John Cheville
- Department of Anatomic and Clinical Pathology, Mayo Clinic, Rochester, MN
| | | | | | - Robert R McWilliams
- Center for Individualized Medicine, Mayo Clinic, Rochester, MN; Mayo Clinic Cancer Center, Rochester, MN
| | - Angela Baker
- Translational Genomics Research Institute, Phoenix, AZ
| | | | | | - Tyler Izatt
- Translational Genomics Research Institute, Phoenix, AZ
| | | | - Irene Cherni
- Translational Genomics Research Institute, Phoenix, AZ
| | - Sara Nasser
- Translational Genomics Research Institute, Phoenix, AZ
| | | | - Lori Cuyugan
- Translational Genomics Research Institute, Phoenix, AZ
| | | | | | | | | | - David W Craig
- Translational Genomics Research Institute, Phoenix, AZ
| | - A Keith Stewart
- Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ; Mayo Clinic Cancer Center, Phoenix, AZ; Center for Individualized Medicine, Mayo Clinic, Rochester, MN
| | | |
Collapse
|